9th October 2023
AACR OVARIAN CANCER CONFERENCE PRESENTATION
• Data from preclinical studies in ovarian cancer presented at premier international conference in
Boston, USA.
• Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
• Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists
I’m guessing it is something to do with this conference ...
.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $111.8M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.8¢ | $883.0K | 3.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 674559 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 225000 | 4 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| ATX (ASX) Chart |